NCT00246662View on ClinicalTrials.gov

Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 14, 2005

Primary Completion Date

December 23, 2008

Study Completion Date

April 30, 2009

Conditions
Leukemia, Lymphocytic, AcuteLeukemia, Nonlymphocytic, AcuteLeukemia, Myeloid, ChronicMyelodysplastic Syndromes
Interventions
DRUG

Vosaroxin

All patients receive vosaroxin Injection

Trial Locations (5)

21231

Johns Hopkins Hospital, Baltimore

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

46202

Indiana University Cancer Center, Indianapolis

77030

University of Texas, MD Anderson Cancer Center, Houston

87196

New Mexico Cancer Care Alliance, Albuquerque

Sponsors
All Listed Sponsors
lead

Sunesis Pharmaceuticals

INDUSTRY